As part of the Nordic EMBL Partnership for Molecular Medicine, FIMM in collaboration with the Doctoral School in Health Sciences (DSHealth) is seeking outstanding candidates for positions of:
in Molecular Medicine, Genomics, Molecular Bioscience, Bioinformatics, Neuroscience, Computational Biomedicine, Drug Research, Data Science, and Artificial Intelligence starting in August 2022
The Institute for Molecular Medicine Finland (FIMM) is an international research institute focusing on human genomics and personalized medicine at the Helsinki Institute of Life Science of the University of Helsinki. FIMM integrates molecular medicine research and technology center and biobanking infrastructures under one roof promoting translational research in grand challenge projects, specifically, the impact of genome information from the Finnish population in personalized health and medicine, individualized cancer medicine, and digital molecular medicine. The areas of interest of the 19 research groups cover cancer, cardiovascular disease, immune disorders, and neurological and psychiatric diseases. A particular focus is to enhance the understanding of sex-based differences in health outcomes, with an emphasis on understudied or sex-biased phenotypes and disorders.
The Doctoral School in Health Sciences (DSHealth) is multidisciplinary and consists of eight internationally and nationally networked doctoral programs that approach life sciences from clinical, molecular and behavioral perspectives. The doctoral school aims to provide systematic, efficient and high-quality doctoral training to prepare doctoral candidates for both professional careers in research and other positions of high expertise.
We currently have four openings for doctoral students who show outstanding potential to become independent researchers and who will significantly benefit from the FIMM-EMBL/DSHealth International PhD rotational training. Specifically, these positions are in the fields of molecular medicine, genomics, bioinformatics, molecular bioscience, data science, drug research, computational biomedicine, neuroscience and artificial intelligence.
Detailed information about the research areas in this call can be found at the following websites and in the application form:
Supervisors and research groups in this call are listed in the application form and in the call announcement.
Qualifications and experience:
Candidates are expected to have a second cycle academic degree (MSc, MD or equivalent) in biology, biochemistry, bioinformatics, biotechnology, cell biology, computer science, genetics, mathematics, medicine, or other related fields, obtained before the start of the position (August 2022). The successful candidate will have good problem solving, troubleshooting, and analytical skills. In addition, the candidate should be fluent in English, have good interpersonal and written and oral communication skills, and be able to work independently as well as in an international team.
Application and selection process:
Candidates are invited to apply online starting January 3, 2022 and submit an application no later than February 6, 2022 at 23:59 Eastern European Time.
To apply, applicants should submit in the online system the following forms in English:
Application form open on January 3, 2022 to be submitted no later than February 6, 2022 at 23:59 Eastern European Time.
Referees’ letters of recommendation (2), submitted no later than February 13, 2022 at 23:59 Eastern European Time. Applicants are asked to fill in the contact information of two referees in the application form. An automated reference request will be sent by email to both referees when the applicant submits the application form.
Please note that candidates are expected to carefully follow the application instructions above. Applications submitted after the deadline, failing to meet the requirements above, or sent directly to group leaders will not be considered.
Application review will begin after the call is closed. Top candidates will be jointly selected by FIMM and DSHealth and invited for two rounds of interviews with a selection committee in mid-March and early April 2022. The final candidates selected for the positions will be offered an initial contract for 18 months, during the first half of which they will engage in training through research group rotations. Upon a successful review and selection of a research group after the rotational period, the initial contract will be extended up to a four-year period.
Further information about:
FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centers for molecular medicine in Norway, Sweden and Denmark, and the EU-LIFE Community. In the beginning of 2017, FIMM joined the University of Helsinki’s new life science research center, Helsinki Institute of Life Science (HiLIFE), as an operational unit.
The Doctoral School in Health Sciences (DSHealth), University of Helsinki consists of eight networked doctoral programs. Each DSHealth doctoral candidate has a personal supervisor for scientific guidance, and a thesis committee to monitor and advise on the progress toward the doctoral degree. DSHealth course offerings and events cover academic topics as well as transferable skills and career planning. When working full time, the aim is to complete the doctoral degree in four years net time.
Helsinki, 21 December 2021
Institute for Molecular Medicine Finland (FIMM)
Doctoral School in Health Sciences (DSHealth)